Renalytix dropped by more than a third as its latest interim results show more big losses and a shrinking cash pile.
Losses are inevitable for an early-stage company such as Renalytix, which is developing diagnostics tools for kidney illness sufferers, but the scale seemingly is raising some alarms.
Revenues for the half year were US$1.2 million, down from US$2.2m a year earlier, while losses were US$19.3m against US$22.6m.
Cash at the end of the period was US$5.6m, but the company is projecting a cash burn of US$23m (US$37m) in the current quarter even with a cost-cutting programme.
Christopher Mills, chairman and James McCullough, CEO, said in a joint statement: “Raising funds to fuel these clear commercial opportunities is essential, particularly now that we have reduced some of the core risks associated with a successful service product launch and adoption.
"In addition to traditional financing efforts, we will continue to explore less dilutive and non-dilutive capital funding sources, particularly now that we have a unique product proposition post-FDA authorization.“
Shares fell 14p to 31.6p.